These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34916317)

  • 1. Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.
    Ozieranski P; Martinon L; Jachiet PA; Mulinari S
    BMJ Open; 2021 Dec; 11(12):e053138. PubMed ID: 34916317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
    Ozieranski P; Martinon L; Jachiet PA; Mulinari S
    Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency.
    Ozieranski P; Saito H; Rickard E; Mulinari S; Ozaki A
    Global Health; 2023 Mar; 19(1):14. PubMed ID: 36869318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries.
    Mulinari S; Martinon L; Jachiet PA; Ozieranski P
    Health Policy; 2021 Jul; 125(7):915-922. PubMed ID: 34006392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016).
    Ozieranski P; Csanádi M; Rickard E; Mulinari S
    BMJ Open; 2020 Sep; 10(9):e037351. PubMed ID: 32950962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis.
    Rickard E; Carmel E; Ozieranski P
    BMJ Open; 2023 Mar; 13(3):e061591. PubMed ID: 36990486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.
    Fabbri A; Santos A; Mezinska S; Mulinari S; Mintzes B
    Int J Health Policy Manag; 2018 Jun; 7(6):504-509. PubMed ID: 29935127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015.
    Ozieranski P; Csanadi M; Rickard E; Tchilingirian J; Mulinari S
    JAMA Netw Open; 2019 Jun; 2(6):e196253. PubMed ID: 31225896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016.
    Stoll M; Hubenschmid L; Koch C; Lieb K
    BMJ Open; 2020 Sep; 10(9):e037395. PubMed ID: 32948560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
    Rickard E; Ozieranski P; Mulinari S
    Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
    Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
    JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota.
    Ross JS; Lackner JE; Lurie P; Gross CP; Wolfe S; Krumholz HM
    JAMA; 2007 Mar; 297(11):1216-23. PubMed ID: 17374816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug company payments to General Practices in England: Cross-sectional and social network analysis.
    Saghy E; Mulinari S; Ozieranski P
    PLoS One; 2021; 16(12):e0261077. PubMed ID: 34874975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.
    Mulinari S; Ozieranski P
    BMJ Open; 2018 Oct; 8(10):e023094. PubMed ID: 30344175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European disclosure of drug company payments lags behind USA.
    Drug Ther Bull; 2022 Sep; 60(9):135. PubMed ID: 36002155
    [No Abstract]   [Full Text] [Related]  

  • 16. Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study.
    Raftery J; Bryant J; Powell J; Kerr C; Hawker S
    Health Technol Assess; 2008 Apr; 12(10):1-128, iii. PubMed ID: 18405468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancies in spine surgeon conflict of interest disclosures between a national meeting and physician payment listings on device manufacturer web sites.
    Buerba RA; Fu MC; Grauer JN
    Spine J; 2013 Dec; 13(12):1780-8. PubMed ID: 23830826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
    Pashley D; Ozieranski P; Mulinari S
    Int J Health Serv; 2022 Jul; 52(3):347-362. PubMed ID: 35230175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financial Conflicts of Interest Among Authors of Urology Clinical Practice Guidelines.
    Carlisle A; Bowers A; Wayant C; Meyer C; Vassar M
    Eur Urol; 2018 Sep; 74(3):348-354. PubMed ID: 29747945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016.
    Ozaki A; Saito H; Senoo Y; Sawano T; Shimada Y; Kobashi Y; Yamamoto K; Suzuki Y; Tanimoto T
    Health Policy; 2020 Jul; 124(7):727-735. PubMed ID: 32439213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.